source
- Boehringer presents phase 1b data on obrixtamig showing strong response rates in second-line small cell lung cancerBoehringer Ingelheim presented updated data from its DAREON-9 phase 1b trial at the ESMO Congress in Madrid, evaluating the DLL3xCD3 bispecific T-cell engager obrixtamig in combination with topotec…
- Biopharma firms curb hiring as $100,000 H-1B visa fee limits foreign talentThe U.S. Department of Homeland Security’s recent increase of the H-1B visa filing fee to $100,000 has made it much more expensive for biopharma employers to sponsor foreign-born scientists and eng…